GeoVax Labs, Inc.(GOVX)

Description: GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

---

Keywords: Biotechnology Cancer Clinical Medicine Infectious Diseases Vaccines Allergy Immunotherapies HIV Hepatitis B Virology Viruses Virus Department Of Defense Fever Immunodeficiency Malaria Ebola U.S. Department Of Defense Chronic Hepatitis Scripps Zika Hiv Vaccine Emory University Modified Vaccinia Ankara Vaccinia

---

Home Page: www.geovax.com

GOVX Technical Analysis

1900 Lake Park Drive
Smyrna, GA 30080
United States
Phone: 678 384 7220

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)